MDxHealth (MDXH) Competitors

$0.80 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.02 (+2.50%)

As of 05/22/2026 07:37 PM Eastern

MDXH vs. TBRG, LAB, SOPH, KRMD, and ZEPP

Should you buy MDxHealth stock or one of its competitors? MarketBeat compares MDxHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MDxHealth include TruBridge (TBRG), Standard BioTools (LAB), SOPHiA GENETICS (SOPH), KORU Medical Systems (KRMD), and Zepp Health (ZEPP). These companies are all part of the "medical info sys" industry.

How does MDxHealth compare to TruBridge?

TruBridge (NASDAQ:TBRG) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

TruBridge has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than TruBridge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TruBridge	$346.84M	1.12	$4.21M	$0.20	129.70
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A

TruBridge has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

TruBridge currently has a consensus target price of $23.95, indicating a potential downside of 7.67%. MDxHealth has a consensus target price of $4.63, indicating a potential upside of 478.13%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than TruBridge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TruBridge	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, TruBridge had 5 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for TruBridge and 0 mentions for MDxHealth. TruBridge's average media sentiment score of 0.14 beat MDxHealth's score of 0.00 indicating that TruBridge is being referred to more favorably in the media.

Company	Overall Sentiment
TruBridge	Neutral
MDxHealth	Neutral

88.6% of TruBridge shares are owned by institutional investors. 10.7% of TruBridge shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TruBridge has a net margin of 0.92% compared to MDxHealth's net margin of -29.90%. TruBridge's return on equity of 18.75% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TruBridge	0.92%	18.75%	8.32%
MDxHealth	-29.90%	-1,078.01%	-22.51%

Summary

TruBridge beats MDxHealth on 13 of the 17 factors compared between the two stocks.

How does MDxHealth compare to Standard BioTools?

MDxHealth (NASDAQ:MDXH) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

MDxHealth currently has a consensus target price of $4.63, indicating a potential upside of 478.13%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 31.07%. Given MDxHealth's stronger consensus rating and higher probable upside, equities research analysts plainly believe MDxHealth is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

MDxHealth has higher revenue and earnings than Standard BioTools. MDxHealth is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Standard BioTools	$85.33M	4.71	-$74.90M	$0.20	5.15

In the previous week, Standard BioTools had 1 more articles in the media than MDxHealth. MarketBeat recorded 1 mentions for Standard BioTools and 0 mentions for MDxHealth. Standard BioTools' average media sentiment score of 0.95 beat MDxHealth's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
MDxHealth	Neutral
Standard BioTools	Positive

53.7% of Standard BioTools shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MDxHealth has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Standard BioTools has a net margin of 73.46% compared to MDxHealth's net margin of -29.90%. Standard BioTools' return on equity of -8.18% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	-1,078.01%	-22.51%
Standard BioTools	73.46%	-8.18%	-6.43%

Summary

Standard BioTools beats MDxHealth on 10 of the 16 factors compared between the two stocks.

How does MDxHealth compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

MDxHealth has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.33	-$79M	-$0.52	N/A
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A

In the previous week, SOPHiA GENETICS had 1 more articles in the media than MDxHealth. MarketBeat recorded 1 mentions for SOPHiA GENETICS and 0 mentions for MDxHealth. SOPHiA GENETICS's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Overall Sentiment
SOPHiA GENETICS	Neutral
MDxHealth	Neutral

SOPHiA GENETICS has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

MDxHealth has a net margin of -29.90% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
MDxHealth	-29.90%	-1,078.01%	-22.51%

31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 1.7% of MDxHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SOPHiA GENETICS currently has a consensus price target of $7.50, suggesting a potential upside of 53.69%. MDxHealth has a consensus price target of $4.63, suggesting a potential upside of 478.13%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

MDxHealth beats SOPHiA GENETICS on 8 of the 15 factors compared between the two stocks.

How does MDxHealth compare to KORU Medical Systems?

MDxHealth (NASDAQ:MDXH) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

KORU Medical Systems has a net margin of -5.27% compared to MDxHealth's net margin of -29.90%. KORU Medical Systems' return on equity of -13.61% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	-1,078.01%	-22.51%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

KORU Medical Systems has lower revenue, but higher earnings than MDxHealth. KORU Medical Systems is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
KORU Medical Systems	$41.13M	4.58	-$2.64M	-$0.05	N/A

MDxHealth has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

MDxHealth currently has a consensus target price of $4.63, suggesting a potential upside of 478.13%. KORU Medical Systems has a consensus target price of $7.25, suggesting a potential upside of 76.83%. Given MDxHealth's higher probable upside, equities research analysts plainly believe MDxHealth is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

58.6% of KORU Medical Systems shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, KORU Medical Systems had 3 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for KORU Medical Systems and 0 mentions for MDxHealth. KORU Medical Systems' average media sentiment score of 0.97 beat MDxHealth's score of 0.00 indicating that KORU Medical Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
MDxHealth	Neutral
KORU Medical Systems	Positive

Summary

KORU Medical Systems beats MDxHealth on 11 of the 15 factors compared between the two stocks.

How does MDxHealth compare to Zepp Health?

MDxHealth (NASDAQ:MDXH) and Zepp Health (NYSE:ZEPP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Zepp Health has a net margin of -15.48% compared to MDxHealth's net margin of -29.90%. Zepp Health's return on equity of -15.00% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	-1,078.01%	-22.51%
Zepp Health	-15.48%	-15.00%	-6.07%

MDxHealth has higher earnings, but lower revenue than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
Zepp Health	$258.90M	0.49	-$40.07M	-$2.51	N/A

MDxHealth has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Zepp Health has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

MDxHealth currently has a consensus target price of $4.63, suggesting a potential upside of 478.13%. Zepp Health has a consensus target price of $56.28, suggesting a potential upside of 552.22%. Given Zepp Health's higher probable upside, analysts plainly believe Zepp Health is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zepp Health	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.6% of Zepp Health shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 36.0% of Zepp Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zepp Health had 2 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Zepp Health and 0 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.00 equaled Zepp Health'saverage media sentiment score.

Company	Overall Sentiment
MDxHealth	Neutral
Zepp Health	Neutral

Summary

Zepp Health beats MDxHealth on 10 of the 15 factors compared between the two stocks.

Get MDxHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXH vs. The Competition

Export

Metric	MDxHealth	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.60M	$1.44B	$6.46B	$12.34B
Dividend Yield	N/A	N/A	2.76%	5.28%
P/E Ratio	-1.23	64.56	21.00	25.66
Price / Sales	0.37	6.30	562.18	86.31
Price / Cash	N/A	22.72	43.49	56.67
Price / Book	-1.95	7.38	10.41	7.14
Net Income	-$33.52M	-$54.76M	$3.57B	$335.98M
7 Day Performance	-4.68%	3.02%	6.40%	4.11%
1 Month Performance	-61.54%	6.69%	3.54%	2.52%
1 Year Performance	-60.78%	1.47%	34.14%	35.04%

MDxHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXH MDxHealth	2.5556 of 5 stars	$0.80 flat	$4.63 +478.1%	-60.8%	$39.60M	$107.88M	N/A	300	Gap Up
TBRG TruBridge	2.7124 of 5 stars	$25.89 flat	$23.95 -7.5%	+9.3%	$388.32M	$345.90M	129.45	3,500
LAB Standard BioTools	3.0571 of 5 stars	$1.01 +2.0%	$1.35 +33.7%	+11.8%	$386.46M	$86.26M	5.05	620	Positive News
SOPH SOPHiA GENETICS	1.9754 of 5 stars	$4.63 -3.3%	$7.50 +62.0%	+71.2%	$328.05M	$77.27M	N/A	520
KRMD KORU Medical Systems	4.4219 of 5 stars	$4.00 -0.5%	$7.25 +81.3%	+54.1%	$184.65M	$41.13M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXH) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MDxHealth (MDXH) Competitors

MDXH vs. TBRG, LAB, SOPH, KRMD, and ZEPP

How does MDxHealth compare to TruBridge?

Summary

How does MDxHealth compare to Standard BioTools?

Summary

How does MDxHealth compare to SOPHiA GENETICS?

Summary

How does MDxHealth compare to KORU Medical Systems?

Summary

How does MDxHealth compare to Zepp Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MDxHealth (MDXH) Competitors

MDXH vs. TBRG, LAB, SOPH, KRMD, and ZEPP

How does MDxHealth compare to TruBridge?

Which has stronger valuation & earnings, TBRG or MDXH?

Which has more volatility and risk, TBRG or MDXH?

Do analysts rate TBRG or MDXH?

Does the media refer more to TBRG or MDXH?

Do institutionals and insiders hold more shares of TBRG or MDXH?

Is TBRG or MDXH more profitable?

Summary

How does MDxHealth compare to Standard BioTools?

Do analysts rate MDXH or LAB?

Which has stronger earnings & valuation, MDXH or LAB?

Does the media favor MDXH or LAB?

Do insiders & institutionals believe in MDXH or LAB?

Which has more risk and volatility, MDXH or LAB?

Is MDXH or LAB more profitable?

Summary

How does MDxHealth compare to SOPHiA GENETICS?

Which has preferable earnings and valuation, SOPH or MDXH?

Does the media prefer SOPH or MDXH?

Which has more volatility and risk, SOPH or MDXH?

Is SOPH or MDXH more profitable?

Do institutionals and insiders have more ownership in SOPH or MDXH?

Do analysts rate SOPH or MDXH?

Summary

How does MDxHealth compare to KORU Medical Systems?

Is MDXH or KRMD more profitable?

Which has better valuation & earnings, MDXH or KRMD?

Which has more risk and volatility, MDXH or KRMD?

Do analysts prefer MDXH or KRMD?

Do insiders and institutionals have more ownership in MDXH or KRMD?

Does the media favor MDXH or KRMD?

Summary

How does MDxHealth compare to Zepp Health?

Is MDXH or ZEPP more profitable?

Which has better valuation & earnings, MDXH or ZEPP?

Which has more risk and volatility, MDXH or ZEPP?

Do analysts prefer MDXH or ZEPP?

Do insiders and institutionals have more ownership in MDXH or ZEPP?

Does the media favor MDXH or ZEPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools